Physician profile
Baha Obaidat
NPI 1437563772
$776.51
in general payments reported to CMS, 2019-2025
12 companies · $451 in 2025
The $451 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.93 · 2022: $42.59 · 2023: $29.83 · 2024: $199 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.33 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $281.98 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $239.34 | 2021-2025 | Tagrisso, Airsupra, Tezspire |
| Baxter Healthcare | $52.34 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $42.44 | 2025 | Tezspire |
| Insmed, INC. | $35.81 | 2022-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $29.50 | 2024 | Winrevair |
| Ethicon INC. | $19.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.78 | 2025 | Dupixent |
| Verona Pharma, INC. | $16.79 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $16.24 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.83 | 2025 | Jascayd |
| United Therapeutics Corporation | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baha Obaidat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.